|
Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC). |
|
|
Consulting or Advisory Role - AstraZeneca; Hengrui Pharmaceutical ; Ignyta; Merck Sharp & Dohme; Roche/Genentech; Syndax |
Research Funding - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Cascade Medical Enterprises |
Stock and Other Ownership Interests - Becton Dickinson; Cascade Medical Enterprises |
Consulting or Advisory Role - Cascade Medical Enterprises |
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
Stock and Other Ownership Interests - Amgen; Immunogen; Teva |
|
|
Stock and Other Ownership Interests - Soligenix |